Economic evaluations of Haemophilus influenzae type b (Hib) vaccine: a systematic review

References

• Makela PH, Takala AK, Peltola H, et al. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992;165(Suppl1):S2-S6
   Google Scholar
• Briere E. Haemophilus influenzae type b. Centers for Disease Control and Prevention; Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th edition. Washington D.C.: Public Health Foundation, 2015 p 119-34
   Google Scholar
• Griffiths UK, Miners A. Economic evaluations of Haemophilus influenzae type b vaccine: systematic review of the literature. Expert Rev Pharmacoecon Outcomes Res 2009;9:333-46
   PubMedGoogle Scholar
• Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72
   PubMed Web of Science ®Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). WHO position paper on Haemophilus influenzae type b conjugate vaccines. Releve epidemiologique hebdomadaire. Wkly Epidemiol Rec 2006;81:445-52
   Google Scholar
• Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004;113:163-74
   PubMed Web of Science ®Google Scholar
• Shin S, Shin YJ, Ki M. Cost-benefit analysis of Haemophilus influenzae type B immunization in Korea. J Kor Med Sci 2008;23:176-84
   PubMed Web of Science ®Google Scholar
• Griffiths UK, Clark A, Hajjeh R. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in low- and middle-income countries: Regional analysis and assessment of major determinants. J Pediat 2013;163(1Suppl):S50-S59
   Web of Science ®Google Scholar
• Knoll MDOBK, Henkle E, Lee E, et al. Global litereture review of Harmophilus influenzae type b and Streptococcus pneumoniae invasive disease among children less than five years of age 1980–2005. Geneva: WHO; 2009
   Google Scholar
• World Health Organization (WHO). Map production Immunization Vaccines and Biologicals (IVB); 2015. http://www.who.int/immunization/en/. [Last accessed 20 January 2016]
   Google Scholar
• Brinsmead R, Hill S, Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediat Infect Dis J 2004;23:32-7
   PubMed Web of Science ®Google Scholar
• World Bank. Data; Country and lending groups; 2016. http://data.worldbank.org/about/country-and-lending-groups. [Last accessed 1 March 2016]
   Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 2010;28:2356-9
   PubMed Web of Science ®Google Scholar
• United States Department of Labor, Bureau of Labor Statistics. Consumer Price Index (CPI) Inflation Calculator. 2016 http://data.bls.gov/cgi-bin/cpicalc.pl. [Last accessed 1 March 2016]
   Google Scholar
• Foreign exchange top (Fxtop). Currency converter. 2016 http://fxtop.com/en/currency-converter-past.php?A=1000&C1=EUR&C2=USD&DD=&MM=&YYYY=2010&B=1&P=&I=1&btnOK=Go%21. [Last accessed 1 March 2016]
   Google Scholar
• Ginsberg GM, Kassis I, Dagan R. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel. J Epidemiol Community Health 1993;47:485-90
   PubMed Web of Science ®Google Scholar
• Harris A, Hendrie D, Bower C, et al. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP. Med J Aust 1994;160:483-8
   PubMed Web of Science ®Google Scholar
• Hay JW, Daum RS. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics 1987;80:319-29
   PubMed Web of Science ®Google Scholar
• Hay JW, Daum RS. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediat Infect Dis J 1990;9:246-52
   PubMed Web of Science ®Google Scholar
• Livartowski A, Boucher J, Detournay B, et al. Cost-effectiveness evaluation of vaccination against Haemophilus influenzae invasive diseases in France. Vaccine 1996;14:495-500
   PubMed Web of Science ®Google Scholar
• McIntyre P, Hall J, Leeder S. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease. Aust J Public Health 1994;18:394-400
   PubMedGoogle Scholar
• Platonov AE, Griffiths UK, Voeykova MV, et al. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation. Vaccine 2006;24:2367-76
   PubMed Web of Science ®Google Scholar
• Pokorn M, Kopac S, Neubauer D, et al. Economic evaluation of Haemophilus influenzae type b vaccination in Slovenia. Vaccine 2001;19:3600-5
   PubMed Web of Science ®Google Scholar
• Trollfors B. Cost-benefit analysis of general vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 1994;26:611-14
   PubMed Web of Science ®Google Scholar
• Zhou F, Bisgard KM, Yusuf HR, et al. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002;110:653-61
   PubMed Web of Science ®Google Scholar
• Garpenholt O, Silfverdal SA, Levin LA. Economic evaluation of general childhood vaccination against Haemophilus influenzae type b in Sweden. Scand J Infect Dis 1998;30:5-10
   PubMed Web of Science ®Google Scholar
• Akumu AO, English M, Scott JA, et al. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bull WHO 2007;85:511-18
   PubMed Web of Science ®Google Scholar
• Broughton EI. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis. J Public Health (Oxf) 2007;29:441-8
   PubMed Web of Science ®Google Scholar
• Clark AD, Griffiths UK, Abbas SS, et al. Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India. J Pediatr 2013;163(1 Suppl):S60-S72
   PubMed Web of Science ®Google Scholar
• Gessner BD, Sedyaningsih ER, Griffiths UK, et al. Vaccine-preventable Haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia. Pediat Infect Dis J 2008;27:438-43
   PubMed Web of Science ®Google Scholar
• Gupta M, Prinja S, Kumar R, et al. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India. Health Policy Plan 2013;28:51-61
   PubMed Web of Science ®Google Scholar
• Le P, Griffiths UK, Anh DD, et al. Cost-effectiveness of Haemophilus influenzae type b vaccine in Vietnam. Vaccine 2015;33:4639-46
   PubMed Web of Science ®Google Scholar
• Limcangco MR, Armour CL, Salole EG, et al. Cost-benefit analysis of a Haemophilus influenzae type b meningitis prevention programme in The Philippines. Pharmacoeconomics 2001;19:391-400
   PubMed Web of Science ®Google Scholar
• Hussey GD, Lesser ML, Reekie WD. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease. S Afr Med J 1995;85:20-5
   PubMed Web of Science ®Google Scholar
• Moradi-Lakeh M, Shakerian S, Esteghamati A. Immunization against Haemophilus influenzae Type b in Iran; cost-utility and cost-benefit analyses. Int J Prev Med 2012;3:332-40
   PubMedGoogle Scholar
• Muangchana C, Warinsatian P. Incorporation of private demand into cost-benefit analysis of a universal Hib vaccination program in Thailand. SE Asian J Trop Med Public Health 2011;42:376-87
   PubMed Web of Science ®Google Scholar
• Gargano LM, Hajjeh R, Cookson ST. Pneumonia prevention during a humanitarian emergency: cost-effectiveness of Haemophilus influenzae type B conjugate vaccine and pneumococcal conjugate vaccine in Somalia. Prehosp Disaster Med 2015;30:402-11
   PubMed Web of Science ®Google Scholar
• Duke T. Haemophilus influenzae type b meningitis: how much better is prevention than cure? P N G Med J 2002;45:213-18
   PubMedGoogle Scholar
• Griffiths UK, Clark A, Shimanovich V, et al. Comparative economic evaluation of Haemophilus influenzae type b vaccination in Belarus and Uzbekistan. PLoS One 2011;6:e21472
   PubMed Web of Science ®Google Scholar
• Niessen LW, ten Hove A, Hilderink H, et al. Comparative impact assessment of child pneumonia interventions. Bull WHO 2009;87:472-80
   PubMed Web of Science ®Google Scholar
• Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ (Clin Research ed) 2001;323:334-6
   PubMed Web of Science ®Google Scholar
• Peltola H. Need for Haemophilus influenzae type b vaccination in Asia as evidenced by epidemiology of bacterial meningitis. Pediat Infect Dis J 1998;17(9Suppl):S148-S51
   Web of Science ®Google Scholar
• Shetty S, Cohen AL, Edmond K, et al. A systematic review and critical evaluation of invasive Haemophilus influenzae type B disease burden studies in Asia from the last decade: lessons learned for invasive bacterial disease surveillance. Pediat Infect Dis J 2010;29:653-61
   PubMed Web of Science ®Google Scholar
• Gessner BD. Haemophilus influenzae type b vaccine impact in resource-poor settings in Asia and Africa. Expert Rev Vaccines 2009;8:91-102
   PubMed Web of Science ®Google Scholar
• Yu H, Yang W, Varma JK. To save children’s lives, China should adopt an initiative to speed introduction of pneumonia vaccines. Health affairs (Project Hope) 2012;31:2545-53
   PubMed Web of Science ®Google Scholar
• Hutubessy R, Chisholm D, Edejer TT. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 2003;1:8
   PubMedGoogle Scholar
• Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. Bull WHO 2016;94:925-30
   PubMed Web of Science ®Google Scholar
• Ottersen T, Forde R, Kakad M, et al. A new proposal for priority setting in Norway: open and fair. Health Policy (Amsterdam, Netherlands) 2016;120:246-51
   PubMed Web of Science ®Google Scholar